Robert James Wills
CIK 1634189 · Executive Chairman · last filed 2026-06-12
Robert James Wills is an Executive Chairman who has filed 49 SEC Form 4 insider transactions across 5 companies since 2015. The most recent filing, for MIST, was dated Jun 12, 2026. Across all open-market trades the lifetime net is +$610.2K, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $256.6K across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$256.6K
5
49
$610.2K
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| MIST | Director | 65,000 | $1.07 | $69.5K | $74.0K | 9 | 2026-06-12 |
| ACOG | Director | 22,241 | $8.41 | $187.0K | $127.3K | 3 | 2026-01-16 |
| Oncternal Therapeutics, Inc. (ONCT) Delisted | Director | 10,000 | $0.53 | $5.3K | $77.4K | 11 | 2024-06-24 |
| CymaBay Therapeutics, Inc. (CBAY) Delisted | Director | 0 | $32.48 | $0 | $95.1K | 16 | 2024-03-22 |
| Oncternal Therapeutics, Inc. (GTXI) Delisted | Executive Chairman | 19,621 | — | — | $236.4K | 10 | 2018-06-26 |
Recent Filings
49 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-06-12 | MIST | Grant (A) | — | $0 | EDGAR |
| 2026-01-16 | ACOG | Grant (A) | +7,241 | $0 | EDGAR |
| 2025-08-21 | ACOG | Buy (P) | +15,000 | $127.3K | EDGAR |
| 2025-07-15 | MIST | Grant (A) | +50,000 | $0 | EDGAR |
| 2025-06-12 | MIST | Grant (A) | — | $0 | EDGAR |
| 2025-04-09 | ACOG | Grant (A) | — | $0 | EDGAR |
| 2024-08-29 | MIST | Grant (A) | — | $0 | EDGAR |
| 2024-06-24 | Oncternal Therapeutics, Inc. (ONCT) Delisted | Grant (A) | — | $0 | EDGAR |
| 2024-04-10 | Oncternal Therapeutics, Inc. (ONCT) Delisted | Buy (P) | +3,086 | $27.7K | EDGAR |
| 2024-04-01 | Oncternal Therapeutics, Inc. (ONCT) Delisted | Buy (P) | +6,914 | $58.6K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.